SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 3.68 |
| Enterprise Value ($M) | -9.13 |
| Book Value ($M) | 15.83 |
| Book Value / Share | 11.97 |
| Price / Book | 0.23 |
| NCAV ($M) | 15.54 |
| NCAV / Share | 11.75 |
| Price / NCAV | 0.24 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.35 |
| Return on Assets (ROA) | -0.66 |
| Return on Equity (ROE) | -0.76 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 14.07 |
| Current Ratio | 14.07 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 16.84 |
| Assets | 17.13 |
| Liabilities | 1.30 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -16.90 |
| Net Income | -21.44 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -18.62 |
| Cash from Investing | 11.65 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Sunstone Life Science Ventures A/S | 2.40 | ||
| 13G/A | Otto Erik | 0.00 | -100.00 | |
| 13D/A | Novo Holdings A/S | 9.20 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,031 | 18,892 | 31.92 | |
| 5,827 | 17,090 | 34.10 | |
| 11,999 | 155,332 | 7.72 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| GELS – Gelteq Limited | GLMD – Galmed Pharmaceuticals Ltd. |
| GLSI – Greenwich LifeSciences, Inc. | GLYC – GlycoMimetics, Inc. |
| GNLX – Genelux Corporation |
Financial data and stock pages provided by
Fintel.io